ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1887

Total-body PET Quantitative Biomarkers Reveal Key Differences in Enthesitis Between Rheumatoid and Psoriatic Arthritis Patients

Dario Mazza1, Siba Raychaudhuri2, Yasser Abdelhafez1 and Abhijit Chaudhari3, 1University of California Davis, Sacramento, CA, 2UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA, 3UC Davis School of Medicine, Sacramento, CA

Meeting: ACR Convergence 2023

Keywords: Biomarkers, Imaging, Psoriatic arthritis, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (1862–1894) Imaging of Rheumatic Diseases Poster II

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: To evaluate the ability of total-body PET (TB-PET) biomarkers to quantify enthesitis in Psoriatic (PsA) and Rheumatoid Arthritis (RA). We hypothesize that objective characterization of specific disease domains will allow PET to reliably distinguish between these two conditions and add to current understanding of their in-vivo pathologies.

Methods: As part of an ongoing study using TB-PET to study autoimmune inflammatory arthritis, we present results of 39 patients (N = 15 with RA and N = 24 with PsA). Participants underwent an ultra-low dose TB-PET/CT scan using the [18F]FDG radiotracer at a single timepoint. Thirty-eight entheses per participant were evaluated on PET images, matching those from the Leeds Enthesitis Index (LEI), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Spondyloarthritis Research Consortium of Canada (SPARCC), Berlin (Major), San Francisco, and 4-point enthesitis measures1.

Each enthesis was graded on a Likert scale (0-3) and the maximum Standardized Uptake Value (SUVmax) was recorded. Summed Likert scale scores and summed SUVmax across all entheses assessed and their average was used to compare between groups. The number of active entheses (scored 2 or more) were counted and compared between groups. Differences between groups were assessed via Mann Whitney U-tests. Receiver operating characteristic (ROC) curves were produced to assess the diagnostic potential of these metrics.

Results: The total number of PET-positive entheses was higher in participants with PsA (8.83 ± 5.1) compared to RA (4.25 ± 2.7, p < 0.05). Across all the 38 entheses sites, there was a significant difference in both summed Likert scale scores and summed SUVmax between groups (p < 0.01), as can be seen in Figure 1. The same metrics assessed for the LEI subset showed no difference between the groups. They did show significant differences for the MASES and SPARCC groupings of entheses (p < 0.05) (Table 1). ROC analysis showed that both summed scores for entheses can perform acceptably as binary classifiers. The best performing measures were those utilizing the San Francisco entheses sites and achieved AUC values of 0.76 (95% CI 0.63-0.90)and 0.79 (95% CI 0.63-0.91) for summed scores and summed SUV max, respectively, followed closely by all entheses sites (0.76, 0.78), MASES (0.74, 0.75), and SPARCC (0.71, 0.72). Summed Likert grades and summed SUVmax performed less well and poorly on the 4-point (0.69, 0.69) and LEI (0.56, 0.58) subsets, respectively.

Conclusion: Our results demonstrate that PET measures can be used to quantify and characterize specific disease domains in autoimmune arthritis. Higher and more frequent uptake in the entheses of PsA patients confirms enthesitis as a core feature of PsA that can potentially distinguish it from RA. Different performance of the various site groupings according to the established enthesitis measures highlight the need for in-depth evaluation of these measures against the standard clinical evaluation and possibly other imaging modalities.

Supporting image 1

Figure 1: (A) Summed Likert grading of active entheses sites for PsA and RA participants; (B) Summed SUV max of active sites in PsA and RA participants.

Supporting image 2

Table 1: Summary of the differences in PET metrics between RA and PsA participants for each subset of entheses assessed. In all cases, PsA patients had higher average scores. Statistically significant results are shown in bold.


Disclosures: D. Mazza: None; S. Raychaudhuri: AbbVie, 2, 5, 6, Amgen, 2, 5, 6, Celgene, 2, 5, 6, Eli Lilly, 2, 5, 6, Janssen, 2, 5, 6, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, SUN Pharma, 2, 5, 6, UCB, 2, 5, 6; Y. Abdelhafez: None; A. Chaudhari: None.

To cite this abstract in AMA style:

Mazza D, Raychaudhuri S, Abdelhafez Y, Chaudhari A. Total-body PET Quantitative Biomarkers Reveal Key Differences in Enthesitis Between Rheumatoid and Psoriatic Arthritis Patients [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/total-body-pet-quantitative-biomarkers-reveal-key-differences-in-enthesitis-between-rheumatoid-and-psoriatic-arthritis-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/total-body-pet-quantitative-biomarkers-reveal-key-differences-in-enthesitis-between-rheumatoid-and-psoriatic-arthritis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology